Early Results of IMRT for Prostate Cancer Treatment
Author Information
Author(s): Anurag K Singh, Peter Guion, Nancy Sears-Crouse, Karen Ullman, Sharon Smith, Paul S Albert, Gabor Fichtinger, Peter L Choyke, Sheng Xu, Jochen Kruecker, Bradford J Wood, Axel Krieger, Holly Ning
Primary Institution: National Cancer Institute
Hypothesis
Can IMRT-based dose escalation effectively target dominant intra-prostatic lesions visible on MRI?
Conclusion
The study shows that IMRT can effectively target and treat dominant intra-prostatic lesions with manageable toxicity.
Supporting Evidence
- All four intra-prostatic lesions were successfully targeted and treated to 94.5 Gy.
- Two patients experienced acute RTOG grade 2 genitourinary toxicity, which resolved by 3 months.
- One patient had no acute toxicity.
Takeaway
Doctors used a special type of radiation therapy to treat cancer spots in the prostate, and it worked well without causing too many side effects.
Methodology
Patients with localized prostate cancer underwent MRI-guided biopsies and received targeted radiation therapy based on MRI findings.
Potential Biases
Potential bias in patient selection and MRI interpretation.
Limitations
The study had a small sample size and short follow-up duration.
Participant Demographics
Three male patients with localized prostate cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website